Candel Therapeutics
Price & Volume
Stats
See more52W Range | $4.35-$9.27 |
Market Cap | $592.7M |
Shares Short | 14M |
Financials
See moreRevenue (12 Mos) | $31,000 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | -$23M |
Diluted EPS | -$1.01 |
News
See moreYahoo Finance • 16 days ago
Candel Therapeutics GAAP EPS of -$0.14 beats by $0.19
Yahoo Finance • last month
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Yahoo Finance • 2 months ago
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Yahoo Finance • 3 months ago
Candel Therapeutics GAAP EPS of -$0.54
About
CEO | Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. |
CFO | Mr. Charles Schoch |
Address | 117 Kendrick Street, Needham, MA, United States, 02494 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 55 |